[
  {
    "ts": null,
    "headline": "Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025",
    "summary": "Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results expected in 2025, enhancing long-term growth prospects.",
    "url": "https://finnhub.io/api/news?id=72c4541b7da7363fd94818cdec79a4380c55699157ee15a82fb1b28506d7dcfb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735476961,
      "headline": "Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025",
      "id": 132195988,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1992633051/image_1992633051.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results expected in 2025, enhancing long-term growth prospects.",
      "url": "https://finnhub.io/api/news?id=72c4541b7da7363fd94818cdec79a4380c55699157ee15a82fb1b28506d7dcfb"
    }
  }
]